After Delays, Nucleonics to Move Hep B Drug To Clinic in '07; Firm Unveils New Rx Goals

After struggling with optimization of its hepatitis B drug candidate, Nucleonics is now on track to begin phase I testing in the first quarter of 2007. The company has also initiated preclinical programs in cancer and influenza.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories